Texas

“The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment,” said Warren Huff, Reata’s chief executive officer and president.

BioSpace takes a quick look at some recent, key industry news that is not related to the coronavirus.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2020. We want to know how the coronavirus outbreak may be impacting your work and your workplace.

Cell Medica has rebranded itself as Kuur Therapeutics as it dives into the development of anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell therapy platform.

The company’s founder and chief executive officer, Ravi Srinivasan, took time to speak with BioSpace to discuss the company and its technology platform.

Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.

Although the concept of genome editing is just starting to gain traction, it has the potential to revolutionize health care by being able to treat, and in many cases cure, previously difficult-to-treat or untreatable genetic diseases. Intellia Therapeutics is focused on implementing a full-spectrum genome editing approach.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

The immuno-oncology therapy, CAR-T, utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged, and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.